The World Market For Next-Generation Cancer Diagnostics Will Reach $1.6 BN In 2015

Tuesday 1 September 2015, Amsterdam

A new report predicts that the world market for next-generation cancer diagnostics will reach $1.6bn in 2015. This forecast and others appear in Next-Generation Cancer Diagnostics Market Forecast 2015-2025: Opportunities for Leading Companies Developing Advanced PCR Techniques, CTC tests, FISH tests, Microarrays and NGS Technologies published in July 2015. Visiongain is a leading business intelligence provider based in London, UK.

The report estimates that the world next-generation cancer diagnostics market was worth $1,437m in 2014. While the number of new cancer cases is expected to reach 24 million by 2035, the cost savings that could be achieved with early diagnosis will be the main driver for the market. Advances in molecular biology will also help expand the cancer diagnostics test menu. Companies wishing to exploit the cancer diagnostics market will need to investigate different next-generation platforms and their applications for each cancer indication.

The report predicts the market will see rapid growth during the forecast period. Companion cancer diagnostics can be costly but we expect them to be increasingly adopted, particularly when choosing expensive cancer therapies. Laboratory automation, standardised commercial cancer tests and affordable benchtop instruments will continue to reduce the costs of molecular testing.

Developed countries currently represent over 80% of the market. Although growth in 2014 was partially offset by slow economic growth and pricing pressures in healthcare, the current outlook for the global economy is stronger than in 2014. Leading companies, in particular, will experience strong growth in developing markets from 2015 to 2025.

The Next-Generation Cancer Diagnostics Market Forecast 2015-2025: Opportunities for Leading Companies Developing Advanced PCR Techniques, CTC tests, FISH tests, Microarrays and NGS Technologies report will be of value to current and future potential investors into the next-generation cancer diagnostics sector, as well as companies and research centres who wish to broaden their knowledge of the next-generation cancer diagnostics market.